Wells Fargo
EVOK

Wells Fargo’s Evoke Pharma EVOK Stock Holding History

Wells Fargo’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$40 – 7065
2024
Q1 		$40 Buy
6
+4
+200% +$34 ﹤0.01% 6885
2023
Q4 		$27 Hold
2
– – ﹤0.01% 7107
2023
Q3 		$33 Buy
2
+1
+100% +$16 ﹤0.01% 7033
2023
Q2 		$28 Hold
1
– – ﹤0.01% 7209
2023
Q1 		$30 Hold
1
– – ﹤0.01% 7255
2022
Q4 		$43 Hold
1
– – ﹤0.01% 7064
2022
Q3 		$0 Sell
1
-1
-50% -$33 ﹤0.01% 6835
2022
Q2 		$0 Buy
2
+1
+100% +$48 ﹤0.01% 6982
2022
Q1 		$0 Hold
1
– – ﹤0.01% 7251
2021
Q4 		$0 Hold
1
– – ﹤0.01% 7365
2021
Q3 		$0 Hold
1
– – ﹤0.01% 7093
2021
Q2 		$0 Hold
1
– – ﹤0.01% 7021
2021
Q1 		$0 Sell
1
-173
-99% -$69.2K ﹤0.01% 6989
2020
Q4 		$65K Buy
174
+173
+17,300% +$89.2K ﹤0.01% 5505
2020
Q3 		$1K Hold
1
– – ﹤0.01% 6197
2020
Q2 		$0 Hold
1
– – ﹤0.01% 6411
2020
Q1 		$0 Buy
+1
New +$192 ﹤0.01% 6348
2018
Q2 		– Sell
-35
Closed -$11K – 6387
2018
Q1 		$11K Sell
35
-84
-71% -$27.6K ﹤0.01% 5921
2017
Q4 		$39K Buy
119
+63
+113% +$26.1K ﹤0.01% 5617
2017
Q3 		$27K Buy
56
+21
+60% +$8.11K ﹤0.01% 5634
2017
Q2 		$13K Hold
35
– – ﹤0.01% 5721
2017
Q1 		$16K Buy
+35
New +$14.3K ﹤0.01% 5756

Other funds holding EVOK

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo's EVOK Position: Q2 2024 in Review

Wells Fargo sold out of Evoke Pharma (EVOK) in Q2 2024, closing a stake of 6 shares — an estimated $40 sold.

Wells Fargo first reported a position in EVOK in Q1 2017 and held it in 22 quarters. The position peaked at $65K in Q4 2020. 16 funds tracked by Wall St. Rank hold EVOK as of Q2 2024.

  • Wells Fargo reported no remaining Evoke Pharma position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 6 Evoke Pharma shares in Q2 2024, an estimated $40.
  • Wells Fargo first reported a position in Evoke Pharma in Q1 2017 and held it in 22 quarters.
  • Wells Fargo's Evoke Pharma position peaked at $65K in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.